A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lexaria Bioscience Corp. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,856 shares of LEXX stock, worth $44,079. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,856
Previous 29,561 46.36%
Holding current value
$44,079
Previous $36,000 58.33%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.29 - $6.25 $17,679 - $85,656
-13,705 Reduced 46.36%
15,856 $57,000
Q4 2023

Feb 14, 2024

BUY
$0.92 - $1.69 $27,196 - $49,958
29,561 New
29,561 $36,000
Q4 2022

Feb 14, 2023

SELL
$2.15 - $2.98 $13,330 - $18,476
-6,200 Reduced 24.93%
18,674 $45,000
Q3 2022

Nov 14, 2022

SELL
$0.74 - $3.17 $2,230 - $9,554
-3,014 Reduced 10.81%
24,874 $61,000

Others Institutions Holding LEXX

About Lexaria Bioscience Corp.


  • Ticker LEXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,951,000
  • Market Cap $16.5M
  • Description
  • Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...
More about LEXX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.